CARE VALUE POLICY

POLICY: Multiple Sclerosis Care Value Policy

DATE REVIEWED: 07/17/2019

DRUGS AFFECTED:

- Avonex® (interferon beta-1a injection [intramuscular] – Biogen Idec)
- Betaseron® (interferon beta-1b injection [subcutaneous] – Bayer)
- Copaxone® (glatiramer acetate injection [20 mg/mL and 40 mg/mL] – Teva, generics)
- Extavia® (interferon beta-1b injection [subcutaneous] – Novartis)
- Glatopa™ (glatiramer acetate injection 20 mg/mL and 40 mg/mL – Sandoz, generic)
- Plegridy™ (peginterferon beta-1a injection – Biogen Idec)
- Rebif® (interferon beta-1a injection, subcutaneous – Serono)
- Aubagio® (teriflunomide tablets – Genzyme/Sanofi)
- Gilenya® (fingolimod capsules – Novartis)
- Mavenclad® (cladribine tablets – EMD Serono)
- Mayzent® (siponimod tablets – Novartis)
- Tecfidera® (dimethyl fumarate delayed-release capsules – Biogen)

OVERVIEW

Several self-administered disease-modifying injectable products are available for use in multiple sclerosis (MS). This Care policy involves the use of the following self-administered injectable products indicated for MS: Avonex, Betaseron, Copaxone (20 mg/mL and 40 mg/mL, generics), Extavia, Glatopa (20 mg/mL and 40 mg/mL), Plegridy and Rebif.1-9 The oral disease-modifying agents used for relapsing forms of MS, Aubagio, Gilenya, Mavenclad, Mayzent, and Tecfidera are also included.10-14 All products are indicated for use in adults. Of note, Gilenya is the only agent specifically indicated for children ≥ 10 to < 18 years of age for the treatment of relapsing forms of MS.10 Mayzent has an indication for use in active secondary progressive MS and its pivotal data involved this patient population.13 Copaxone has very limited data in this patient subset. A practice guideline recommendation regarding disease-modifying agents for adults with MS from the American Academy of Neurology (2018) states Gilenya as one of the agents to consider for patients with MS who have highly active disease. For more information on criteria within a Prior Authorization (PA) Policy refer to the respective policies.15-24

POLICY STATEMENT

This Care Value program requires the patient to meet the respective ESI Standard Prior Authorization Policy criteria. Patients are directed to try one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL) prior to approval of a Non-Preferred Product. All approvals for are provided for 1 year in duration. Of note, only Non-Preferred Drugs are required to undergo prior authorization.
**Automation:** None.

**Documentation:** In the *Multiple Sclerosis – Care Value Policy*, documentation is required for initiation of therapy where noted in the criteria as [documentation required]. Documentation may include, but is not limited to, chart notes and magnetic resonance imaging (MRI) reports.

**Preferred Product:** generic glatiramer 20 mg/mL, generic glatiramer 40 mg/mL

**Non-Preferred Products:** Avonex, Betaseron, Copaxone 20 mg/mL, Copaxone 40 mg/mL, Extavia, Glatopa 20 mg/mL, Glatopa 40 mg/mL, Plegridy, Rebif, Aubagio, Gilenya, Mayzent, Mavenclad, Tecfidera

**RECOMMENDED EXCEPTION CRITERIA**

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Exception</th>
</tr>
</thead>
</table>
| **Avonex** | 1. The patient must meet the following criteria (A and B):  
   A) The patient meets the *ESI Standard Multiple Sclerosis – Avonex Prior Authorization Policy* criteria; AND  
   B) The patient meets one of the following (i or ii):  
   i. The patient has been established on Avonex for ≥ 120 days; OR  
   ii. The patient meets both of the following (a and b):  
   a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND  
   b) The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescriber. (Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts). |
| **Aubagio** | 1. The patient must meet the following criteria (A and B):  
   A) The patient meets the *ESI Standard Multiple Sclerosis – Aubagio Prior Authorization Policy* criteria; AND  
   B) The patient meets one of the following (i or ii):  
   i. The patient has been established on Aubagio for ≥ 120 days; OR  
   ii. The patient meets both of the following (a and b):  
   a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND  
   b) The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescriber. (Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts). |
<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Exception</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Betaseron</strong></td>
<td>1. The patient must meet the following criteria (A and B):</td>
</tr>
<tr>
<td></td>
<td>A) The patient meets the <em>ESI Standard Multiple Sclerosis – Betaseron/Extavia Prior Authorization Policy</em> criteria; AND</td>
</tr>
<tr>
<td></td>
<td>B) The patient meets one of the following (i or ii):</td>
</tr>
<tr>
<td></td>
<td>i. The patient has been established on Betaseron for ≥ 120 days; OR</td>
</tr>
<tr>
<td></td>
<td>ii. The patient meets both of the criteria (a and b):</td>
</tr>
<tr>
<td></td>
<td>a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND</td>
</tr>
<tr>
<td></td>
<td>b) The patient has an unacceptable toxicity and/or suboptimal efficacy according to the prescriber. (Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts).</td>
</tr>
<tr>
<td><strong>Copaxone 20 mg/mL</strong></td>
<td>1. The patient must meet the following criteria (A and B):</td>
</tr>
<tr>
<td></td>
<td>A) The patient meets the <em>ESI Standard Multiple Sclerosis – Copaxone/Glatopa PA Policy</em> criteria; AND</td>
</tr>
<tr>
<td></td>
<td>B) The patient meets both of the following (i and ii):</td>
</tr>
<tr>
<td></td>
<td>i. The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND</td>
</tr>
<tr>
<td></td>
<td>ii. Brand Copaxone 20 mg/mL is being requested due to a formulation difference in the inactive ingredient(s) [e.g., preservatives] between the Brand and the bioequivalent generic product which, per the prescribing physician, has or would result in a significant allergy or serious adverse reaction.</td>
</tr>
<tr>
<td><strong>Copaxone 40 mg/mL</strong></td>
<td>1. The patient must meet the following criteria (A and B):</td>
</tr>
<tr>
<td></td>
<td>A) The patient meets the <em>ESI Standard Multiple Sclerosis – Copaxone/Glatopa PA Policy</em> criteria; AND</td>
</tr>
<tr>
<td></td>
<td>B) The patient meets both of the following (i and ii):</td>
</tr>
<tr>
<td></td>
<td>i. The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND</td>
</tr>
<tr>
<td></td>
<td>ii. Brand Copaxone 40 mg/mL is being requested due to a formulation difference in the inactive ingredient(s) [e.g., preservatives] between the Brand and the bioequivalent generic product which, per the prescriber, has or would result in a significant allergy or serious adverse reaction.</td>
</tr>
<tr>
<td><strong>Extavia</strong></td>
<td>1. The patient must meet the following criteria (A and B):</td>
</tr>
<tr>
<td></td>
<td>A) The patient meets the <em>ESI Standard Multiple Sclerosis – Betaseron/Extavia Prior Authorization Policy</em> criteria; AND</td>
</tr>
<tr>
<td></td>
<td>B) The patient meets one of the following (i or ii)</td>
</tr>
<tr>
<td></td>
<td>i. The patient has been established on Extavia for ≥ 120 days; OR</td>
</tr>
<tr>
<td></td>
<td>ii. The patient meets both of the following (a and b):</td>
</tr>
<tr>
<td></td>
<td>a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND</td>
</tr>
<tr>
<td></td>
<td>b) The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescriber. (Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts).</td>
</tr>
<tr>
<td>Trade Name</td>
<td>Exception</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
| **Gilenya** | 1. The patient must meet the following criteria (A and B):  
   A) The patient meets the *ESI Standard Multiple Sclerosis – Gilenya Care Value Policy* criteria; AND  
   B) The patient meets one of the following (i, ii, iii or iv):  
      i. The patient has been established on Gilenya for ≥ 120 days; OR  
      ii. The patient is a child ≥ 10 to < 18 years of age; OR  
      iii. According to the prescriber the patient has highly-active or aggressive multiple sclerosis by meeting one of the following (a, b, c, or d):  
         a) The patient has demonstrated rapidly-advancing deterioration(s) in physical functioning (e.g., loss of mobility/or lower levels of ambulation, severe changes in strength or coordination) [documentation required]; OR  
         b) Disabling relapse(s) with suboptimal response to systemic corticosteroids [documentation required]; OR  
         c) Magnetic resonance imaging [MRI] findings suggest highly-active or aggressive multiple sclerosis (e.g., new, enlarging, or a high burden of T2 lesions or gadolinium-enhancing lesions) [documentation required]; OR  
         d) Manifestations of multiple sclerosis-related cognitive impairment [documentation required]; OR  
      iv. The patient meets both of the following (a and b):  
         a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND  
         b) The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescribing physician. (Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts). |
| **Glatopa 20 mg/mL** | 1. The patient must meet the following criteria (A and B):  
   A) The patient meets the *ESI Standard Multiple Sclerosis – Copaxone/Glatopa PA Policy* criteria; AND  
   B) The patient meets both of the following (i and ii):  
      i. The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND  
      ii. Brand Glatopa 20 mg/mL is being requested due to a formulation difference in the inactive ingredient(s) [e.g., preservatives] between the Brand and the bioequivalent generic product which, per the prescriber, has or would result in a significant allergy or serious adverse reaction. |
| **Glatopa 40 mg/mL** | 1. The patient must meet the following criteria (A and B):  
   A) The patient meets the *ESI Standard Multiple Sclerosis – Copaxone/Glatopa PA Policy* criteria; AND  
   B) The patient meets both of the following (i and ii):  
      i. The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND  
      ii. Brand Glatopa 40 mg/mL is being requested due to a formulation difference in the inactive ingredient(s) [e.g., preservatives] between the Brand and the bioequivalent generic product which, per the prescriber, has or would result in a significant allergy or serious adverse reaction. |
<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Exception</th>
</tr>
</thead>
</table>
| Mayzent    | 1. The patient must meet the following criteria (A and B):  
|            | A) The patient meets the *ESI Standard Multiple Sclerosis – Mayzent Prior Authorization Policy* criteria; AND  
|            | B) The patient meets one of the following (i or ii):  
|            | i. The patient has been established on Mayzent for ≥ 120 days; OR  
|            | ii. The patient meets one of the following (a or b):  
|            | a) The patient has active secondary progressive multiple sclerosis; OR  
|            | b) The patient meets both of the following criteria (1 and 2):  
|            | 1. The patient has tried one Preferred Product product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND  
|            | 2. The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescriber. (Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts). |
| Mavenclad  | 1. The patient must meet the following criteria (A and B):  
|            | A) The patient meets the *ESI Standard Multiple Sclerosis – Mavenclad Prior Authorization Policy* criteria; AND  
|            | B) The patient meets one of the following (i or ii):  
|            | i. The patient has been established on Mavenclad for ≥ 120 days; OR  
|            | ii. The patient meets both of the following (a and b):  
|            | a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND  
|            | b) The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescriber. (Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts). |
| Plegridy   | 1. The patient must meet the following criteria (A and B):  
|            | A) The patient meets the *ESI Standard Multiple Sclerosis – Plegridy Prior Authorization Policy* criteria; AND  
|            | B) The patient meets one of the following (i or ii):  
|            | i. The patient has been established on Plegridy for ≥ 120 days; OR  
|            | ii. The patient meets both of the criteria below (a and b):  
|            | a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND  
<p>|            | b) The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescriber. (Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber physician] also counts). |</p>
<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Exception</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rebif</td>
<td>1. The patient must meet the following criteria (A and B):&lt;br&gt;   <strong>A)</strong> The patient meets the <em>ESI Standard Multiple Sclerosis – Rebif Prior Authorization Policy</em> criteria; AND&lt;br&gt;   <strong>B)</strong> The patient meets one of the following (i or ii):&lt;br&gt;      i. The patient has been established on Rebif for ≥ 120 days; OR&lt;br&gt;      ii. The patient meets both of the criteria below (a and b):&lt;br&gt;         a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND&lt;br&gt;         b) The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescriber. <em>(Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts).</em></td>
</tr>
<tr>
<td>Tecfidera</td>
<td>1. The patient must meet the following criteria (A and B):&lt;br&gt;   <strong>A)</strong> The patient meets the <em>ESI Standard Multiple Sclerosis – Tecfidera Prior Authorization Policy</em> criteria; AND&lt;br&gt;   <strong>B)</strong> The patient meets one of the following (i or ii):&lt;br&gt;      i. The patient has been established on Tecfidera for ≥ 120 days; OR&lt;br&gt;      ii. The patient meet both of the following (a and b):&lt;br&gt;         a) The patient has tried one Preferred Product (generic glatiramer 20 mg/mL or generic glatiramer 40 mg/mL); AND&lt;br&gt;         b) The patient has had unacceptable toxicity and/or suboptimal efficacy according to the prescriber. <em>(Note: Prior use of Brand Name Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, or Glatopa 40 mg/mL with unacceptable toxicity and/or suboptimal efficacy [according to the prescriber] also counts).</em></td>
</tr>
</tbody>
</table>

**REFERENCES**

5. Glatiramer acetate injection 20 mg/mL [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; November 2018.
Multiple Sclerosis Care Value Policy
Page 7


**HISTORY**

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes*</th>
<th>TAC Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy</td>
<td>--</td>
<td>12/13/2017</td>
</tr>
<tr>
<td>Selected revision</td>
<td>Added Glatopa 40 mg/mL to the criteria are appropriate.</td>
<td>02/21/2018</td>
</tr>
<tr>
<td>Selected revision</td>
<td>Added criteria which permits exceptions for Gilenya for use if the patient is a child aged ≥ 10 to &lt; 18 years of age.</td>
<td>05/23/2018</td>
</tr>
<tr>
<td>Annual revision</td>
<td>Exception criteria were added for Gilenya to approve Gilenya if, according to the prescribing physician, the patient has highly-active or aggressive multiple sclerosis and that one of the following conditions is met, along with corresponding documentation requirements: the patient has demonstrated rapidly-advancing deterioration(s) in physical functioning (e.g., loss of mobility/or lower levels of ambulation, severe changes in strength or coordination); disabling relapse(s) with suboptimal response to systemic corticosteroids; magnetic resonance imaging findings suggest highly-active or aggressive multiple sclerosis (e.g., new, enlarging, or a high burden of T2 lesions or gadolinium-enhancing lesions); OR manifestations of multiple sclerosis-related cognitive impairment.</td>
<td>10/31/2018</td>
</tr>
<tr>
<td>Annual revision</td>
<td>Extavia was added to the program (effective 1/1/2019) and placed in Step 2 with related criteria added.</td>
<td>10/31/2018</td>
</tr>
<tr>
<td>Selected revision</td>
<td>Mayzent and Mavenclad were added as Non-Preferred products. As such, exception criteria were added for Mayzent and Mavenclad that are similar to those for the other oral multiple sclerosis medications (e.g., Tecfidera, Aubagio). For Mayzent, an additional exception was added for patients with secondary progressive multiple sclerosis. There were no other changes to the criteria.</td>
<td>06/12/2019</td>
</tr>
<tr>
<td>Early annual revision</td>
<td>The following medications were added to the rule as Non-Preferred Products: Copaxone 20 mg/mL, Copaxone 40 mg/mL, Glatopa 20 mg/mL, Avonex, Betaseron, Rebif, and Plegridy. New criteria were developed. Also, Step 1 and Step 2 agents are now referred to as “Preferred Products” and “Non-Preferred Products”, respectively. It was clarified that only Non-Preferred Products are required to undergo prior authorization. The following criteria changes were made: 1. <strong>Mayzent:</strong> The descriptor “active” was added to the diagnosis of secondary progressive multiple sclerosis. 2. <strong>All Non-Preferred Products:</strong> Criteria that had the wording “according to the prescribing physician” were changed to state “according to the prescriber”. For Mayzent, the criteria that allows exceptions if the patient has secondary progressive multiple sclerosis had “active” added as a descriptor.</td>
<td>07/17/2019 (Effective 8/9/2019)</td>
</tr>
</tbody>
</table>

TAC – Therapeutic Assessment Committee; * For a further summary of criteria changes, refer to respective TAC minutes available at: [http://esidepartments/sites/Dep043/Committees/TAC/Forms/AllItems.aspx](http://esidepartments/sites/Dep043/Committees/TAC/Forms/AllItems.aspx).

---

© 2019 Express Scripts Holding Company. All Rights Reserved.
This document is confidential and proprietary to Express Scripts Holding Company. Unauthorized use and distribution are prohibited.